mfine Raises INR 31 crore in Venture Debt from Alteria Capital

IMT News Desk
IMT News Desk
· 3 min read

The healthtech AI startup is set to expand hospital network toDelhi NCR, Kolkata, Mumbai, Chennai in the next 6 months

Plans afoot to onboard over 2500 doctors from 250 hospitals and reach 150,000 consultations per month in the next one year

Bengaluru, July 2, 2019: mfine, a health-tech AI startup that enables virtual medical consultations has raised INR 31 crore in total, as venture debt from Alteria Capital, India’s largest venture debt fund. The investment is a testament to mfine’s continued growth in India. In June alone, over 25,000 transactions were completed on mfine with the customer base growing 30% month over month. In the next six months, mfine will foray into Delhi NCR, Mumbai, Chennai  and Kolkata. mfine also recently raised $17.2M in series B from SBI Investment, SBI Ven Capital, Stellaris Venture Partners and Prime Venture Partners.  

mfine follows a unique model of partnering with leading and trusted hospitals instead of aggregating individual doctors on its platform.   mfine has already built a network of 160 such hospitals across 5 cities. Hospital partnerships enable mfine to make high quality care of trusted doctors available on a digital channel. Specialist doctors from these hospitals are assisted by mfine’s AI system, improving their efficiency & effectiveness dramatically. mfine’s care team of more than 80 in-house doctors are working alongside the AI system, offering best possible diagnosis and care. The AI engine has the ability to diagnose and triage over 1200 common diseases, read hundreds of health parameters in the diagnostic reports thus saving significant time for the doctors.

mfine aims to be one of the largest virtual hospitals in the world with services across primary care, secondary care and chronic care management including auxiliary services like medicine delivery and diagnostic tests. In the next 12 months, it will bring together India’s top 250 hospitals, from 10 cities with more than 2500 doctors onto its virtual hospital platform. The company will be tripling its investments in AI, mobile engineering and hardware integration. 

Alteria Capital is India’s largest venture debt fund with an INR 800 crore corpus and a greenshoe option of INR 200 crore. Alteria provides venture debt in the range of INR 5 – 100 crore to venture backed companies. Alteria’s current portfolio includes Faasos, Portea, Fingerlix (Maverix Platforms Pvt Ltd), Toppr Technologies Ltd, Raw Pressery, Vogo Bikes, Dunzo, Vinculum, Mfine, Zest Money, Stanza Living, Country Delight, Loadshare, Limetray and Universal Sportsbiz Pvt Ltd (Wrogn, Imara & Ms. Taken brands).

mfine was founded in February 2017 by Ashutosh Lawania (Myntra co-founder) and Prasad Kompalli, a former business head at Myntra. The founders were later joined by Ajit Narayanan, ex-Myntra CTO, Arjun Choudhary, ex-Myntra head of growth marketing. Including the current funding round, the startup has raised over $28 million and has 300 employees in Bengaluru & Hyderabad.

The mfine app is currently available in English on Google Playstore and App Store: http://bit.ly/mfine-care

Supporting Quotes

Prasad Kompalli, CEO & cofounder, mfine

At mfine we are continuing to see traction both in provider network and consumer adoption. We are able to bring high quality healthcare to users’ mobile, be it doctor consultations, medicine orders, diagnostics tests or digital tools. The recently closed series B and Alteria’s current investment are an endorsement of our differentiation and potential to create a large scale health-tech business.

Vinod Murali, Managing Partner, Alteria Capital

We double down on opportunities where companies are performing visibly well and provide frictionless access to capital. We are very excited to have the opportunity to contribute further to the mfine journey in a substantive manner as they change the landscape of healthcare technology in India.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk